8-K: Lyell Immunopharma Unveils Strong Ronde-cel Data at ASH

Lyell Immunopharma presented promising clinical and translational data for its CAR T-cell therapy ronde-cel in large B-cell lymphoma at the ASH Annual Meeting.

Summary

• Ronde-cel (LYL314), a dual-targeting CD19/CD20 CAR T-cell product, showed high efficacy in 69 CAR T-cell naive patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL).
• In 29 efficacy-evaluable patients in the thirdor later-line (3L+) setting, the overall response rate (ORR) was 93% (27/29), with 76% (22/29) achieving a complete response (CR).
• 72% (13/18) of 3L+ patients with CR remained in CR at 6 months or longer, and the median progression-free survival (PFS) was 18 months.
• In 18 efficacy-evaluable patients in the second-line (2L) setting (94% with primary refractory disease), the ORR was 83% (15/18), with 61% (11/18) achieving a CR.
• 70% (7/10) of 2L patients with CR remained in CR at 6 months, and the median duration of complete response (DoCR) was not reached.
• A manageable safety profile was observed across all 69 patients, appropriate for potential outpatient administration.
• No Grade 3 or greater cytokine release syndrome (CRS) was observed, with low rates of Grade 1 (32%) or Grade 2 (29%) CRS.
• One case (4%) of Grade 3 or greater immune effector cell-associated neurotoxicity syndrome (ICANS) was reported, with Grade 1 (9%), Grade 2 (3%), and Grade 3 or greater (12%) ICANS rates overall.
• The median time to complete resolution of all ICANS reports was 4 days, and no deaths were determined to be related to ronde-cel administration.
• Translational data indicated that ronde-cel, manufactured with CD62L enrichment, achieved robust expansion and high expression of memory-related genes after infusion.
• Ronde-cel demonstrated a higher proportion of CD62L-positive T cells with a memory-cell phenotype prior to infusion and up to a three-fold higher expansion in patients compared to approved CD19 CAR T-cell products like axi-cel and tisagenlecleucel.

Sentiment

Score: 9

Explanation: The clinical and translational data presented for ronde-cel are highly positive, demonstrating strong efficacy, a differentiated and manageable safety profile (especially the lack of high-grade CRS), and superior biological characteristics compared to existing therapies. This significantly de-risks the asset and enhances its commercial potential.

Positives

• High overall response rates: 93% in 3L+ patients and 83% in 2L patients with R/R LBCL.
• Strong complete response rates: 76% in 3L+ patients and 61% in 2L patients.
• Durable responses with 72% of 3L+ CR patients remaining in CR at 6 months or longer, and median PFS of 18 months.
• Manageable safety profile with no Grade 3 or greater cytokine release syndrome (CRS) observed.
• Potential for outpatient administration due to the favorable safety profile.
• Translational data shows superior memory-cell phenotype and up to three-fold higher CAR T-cell expansion compared to approved CD19 CAR T-cell products (axi-cel, tisa-cel).
• No deaths were determined to be related to ronde-cel administration.

Risks

• Immune effector cell-associated neurotoxicity syndrome (ICANS) was reported, including one case (4%) of Grade 3 or greater, and overall rates of Grade 1 (9%), Grade 2 (3%), and Grade 3 or greater (12%).
• The patient population was heavily pre-treated and high-risk, which can present challenges in treatment response and safety.

Future Outlook

Ronde-cel is currently in pivotal development for patients with relapsed and/or refractory large B-cell lymphoma, indicating progression towards potential regulatory approval.

Management Comments

• A manageable safety profile appropriate for outpatient administration was observed.

Industry Context

The CAR T-cell therapy market for large B-cell lymphoma is highly competitive, with several approved CD19-targeting products. Ronde-cel's dual CD19/CD20 targeting and enhanced memory T-cell profile aim to differentiate it by potentially offering improved efficacy and a more favorable safety profile, particularly the absence of high-grade CRS, which could be a significant advantage for patient management and broader adoption.

Comparison to Industry Standards

• Ronde-cel demonstrated a higher proportion of CD62L-positive T cells with a memory-cell phenotype prior to infusion compared to published data for axi-cel (N=110) and tisagenlecleucel (tisa-cel, N=31).
• Ronde-cel showed up to a three-fold higher expansion in patients after infusion compared to the expansion of approved CD19 CAR T-cell products.
• The observed manageable safety profile, particularly the absence of Grade 3 or greater cytokine release syndrome (CRS), suggests a potentially better safety profile compared to some existing CAR T therapies which often report higher rates of severe CRS.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potentially increasing company valuation and future revenue prospects.
• Patients: Potential for a new, highly effective, and potentially safer treatment option for R/R LBCL, especially with outpatient administration possibility.
• Healthcare Providers: Easier administration if outpatient is feasible, potentially reducing healthcare burden and costs associated with CAR T-cell therapy.

Next Steps

• Continue pivotal development of ronde-cel for patients with relapsed and/or refractory large B-cell lymphoma.

Key Dates

Recommendation

The clinical data for ronde-cel demonstrates high efficacy (ORR, CR, PFS) in a heavily pre-treated, high-risk LBCL patient population, including those with primary refractory disease. Crucially, the safety profile appears highly differentiated with no Grade 3+ CRS and potential for outpatient administration, addressing a major challenge with current CAR T therapies. Translational data further supports a superior product profile with enhanced memory cell characteristics and expansion compared to approved competitors. This strong data package significantly de-risks the asset and positions Lyell for potential market leadership in a competitive but high-value therapeutic area, warranting a strong buy recommendation.

Keywords

Lyell Immunopharma, LYL314, ronde-cel, CAR T-cell, LBCL, large B-cell lymphoma, ASH, clinical trial, oncology, hematology, CD19, CD20, cell therapy, immunotherapy, relapsed refractory